Urteste S.A. (WSE:URT)

Market Cap	74.78M +8.3%
Revenue (ttm)	2.50M +62.3%
Net Income	-7.10M
EPS	-4.94
Shares Out	1.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,114
Open	50.20
Previous Close	49.00
Day's Range	47.50 - 50.20
52-Week Range	24.00 - 72.20
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 29, 2026

About Urteste

Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdańsk, Poland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 38
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: URT

Financial Performance

In 2025, Urteste's revenue was 2.50 million, an increase of 39.11% compared to the previous year's 1.80 million. Losses were -5.98 million, 64.7% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 3, 2026

Data Sources Report a data error